Lantheus Holdings Inc

1LNTH

Company Profile

  • Business description

    Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

  • Contact

    201 Burlington Road
    South Building
    BedfordMA01730
    USA

    T: +1 978 671-8001

    E: [email protected]

    https://www.lantheus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    808

Stocks News & Analysis

stocks

Chart of the Week: Opportunities with wide-moat retailers

Consumer defensive names look undervalued.
stocks

New ASX share added to our best ideas

Earnings outlook is strong and the shares trade at a discount to our fair value.
stocks

Fair value downgraded for ASX heavyweight

Our capital allocation rating was also lowered due to balance sheet weakness.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,190.207.50-0.08%
CAC 407,966.9571.010.90%
DAX 4024,113.62232.900.98%
Dow JONES (US)46,441.1043.210.09%
FTSE 1009,446.4396.001.03%
HKSE26,855.56232.680.87%
NASDAQ22,755.1695.150.42%
Nikkei 22544,783.24232.390.52%
NZX 50 Index13,423.6410.35-0.08%
S&P 5006,711.2022.740.34%
S&P/ASX 2008,899.606.20-0.07%
SSE Composite Index3,882.7820.250.52%

Market Movers